Biotech Co. Misled Investors About Kidney Drug, Suit Says
Biotechnology company Ardelyx Inc. has been hit with a derivative shareholder suit alleging its top brass engaged in insider trading and made false and misleading statements about a drug for patients...To view the full article, register now.
Already a subscriber? Click here to view full article